| References: |
GPR39-C3 is the first potent, selective and orally bioavailable GPR39 agonist with an EC50 ~0.8 nM for human GPR39 and ~0.4 nM for rodent GPR39. It has no inhibitory effects (at 10 μM) on a panel of kinases and exhibits no relevant binding affinity for the related ghrelin and neurotensin-1 receptors and other enzymes, transporters, and GPCRs. GPR39-C3 has excellent functional activity in physiologically relevant rodent cells and in vivo. An acute study in normal mice with orally administrated GPR39-C3 confirmed in vitro findings by demonstrating an increase of the relevant pharmacodynamic marker GLP-1. It is a good chemical tool to enable interrogation of GPR39 signaling in different cellular contexts. For the detailed information of GPR39-C3, the solubility of GPR39-C3 in water, the solubility of GPR39-C3 in DMSO, the solubility of GPR39-C3 in PBS buffer, the animal experiment (test) of GPR39-C3, the cell expriment (test) of GPR39-C3, the in vivo, in vitro and clinical trial test of GPR39-C3, the EC50, IC50,and affinity,of GPR39-C3, For the detailed information of GPR39-C3, the solubility of GPR39-C3 in water, the solubility of GPR39-C3 in DMSO, the solubility of GPR39-C3 in PBS buffer, the animal experiment (test) of GPR39-C3, the cell expriment (test) of GPR39-C3, the in vivo, in vitro and clinical trial test of GPR39-C3, the EC50, IC50,and affinity,of GPR39-C3, Please contact DC Chemicals. |
